gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · AMGNHealthcareBiotechnology

Amgen Inc (AMGN)

$478.48+3.73%
Close Nov 4, 2026 · split-adjusted
Nov 4, 2026$478.48▲ 61.27% in range
Nov 4, 2025Low $296.70 · High $478.48Nov 4, 2026
What changed · written from our data
As of Nov 4, 2026

Amgen closed at $478.48 on Nov 4, up 3.73% — matching its 52-week closing high. Volume of 4.6M shares was 1.75× its 20-day average (above normal).

Split-adjusted performance: +18.8% over one month, +44.5% over six months, +61.5% over one year.

In the quarter ended Jun 30, 2026, revenue was $10.05B, up 9.5% from a year earlier, with a net margin of 23.6%.

Short interest was 13.4M shares at the Oct 15 settlement, down 4.6% from the prior report (2.5% of float, 5.0 days to cover).

Market cap$258.68B540.6M shares
Revenue · quarter$10.05B+9.5% YoY
Diluted EPS$4.37+64.9% YoY
P/E · TTM29.6×P/S 6.8×
Net margin23.6%Gross 72.0%
Dividend yield2.11%$2.52 last paid
52-week range296.30 – 478.480.0% from high
Volume4.6M1.75× 20-day avg
Volatility · 60d33.8%Annualised
Short % of float2.5%5.0 days to cover
Net cash-$43.31BCash $13.99B
Next earnings—Not scheduled
Split-adjusted performance
1W +5.9%1M +18.8%3M +18.2%6M +44.5%YTD +46.2%1Y +61.5%3Y +81.8%5Y +131.6%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Biotechnology

Percentile among 139 companies (100 = best)

6-month momentum88
Revenue growth53
Net margin84
Value (low P/E)39
Size100

Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.

Short interest

Details →
Shares short13.4M−4.6% vs prior
Days to cover5.0Settled Oct 15
% of float2.5%
Short vol. 10d54.6%of daily volume

Closest peers by size in Biotechnology

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
AMGNAmgen$478.48+3.73%+44.5%+9.5%23.6%29.6$258.68B
GILDGilead Sciences$174.48+4.19%+28.0%+6.8%29.3%—$216.41BCompare
MRNAModerna$258.38+13.11%+429.6%+2.1%−539.3%—$103.15BCompare
RVMDRevolution Medicines$199.70+2.82%+32.2%———$42.80BCompare
BIIBBiogen$254.46+2.22%+33.4%+10.6%−0.7%108.2$37.61BCompare
EXELExelixis$72.75+0.61%+49.4%+10.2%33.1%20.1$17.75BCompare
NBIXNeurocrine Biosciences$166.05+0.73%+12.9%+41.2%18.4%24.0$16.88BCompare
HALOHalozyme Therapeutics$130.34+1.34%+96.4%+47.7%47.8%35.8$14.79BCompare
KYMRKymera Therapeutics$136.25+7.21%+58.0%−100.0%——$11.63BCompare

News about Amgen

All news →
AMGN Q3 Earnings Call Highlights Pipeline and Raised OutlookZacks Investment Research · 16h ago▲ PositiveAmgen (AMGN) Reports Q3 Earnings: What Key Metrics Have to SayZacks Investment Research · 1d ago▲ PositiveAmgen Just Gave Its Shareholders Great NewsThe Motley Fool · 2d ago▲ PositiveBeat the Market Like Zacks: Marathon Petroleum, Amgen, Chevron in FocusZacks Investment Research · 2d ago▲ PositiveLooking For Growth, Income, and Stability? This Stock Could Offer All 3The Motley Fool · 4d ago▲ Positive

Quick answers

What does Amgen do?
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases.
What is AMGN's market cap?
$258.68B, based on the Nov 4 close of $478.48.
What is AMGN's P/E ratio?
29.6× trailing-twelve-month earnings of $8.74B.
Does Amgen pay a dividend?
Yes. The latest regular dividend was $2.52 per share (ex-date Aug 21), an annualised yield of 2.11%.
How much of AMGN is sold short?
13.4M shares, 2.5% of float, as of Oct 15, 2026.
What sector is AMGN in?
Healthcare, in the Biotechnology industry.

About Amgen

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

HQ: Thousand Oaks, CA31,500 employeesListed Jun 17, 1983amgen.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology